https://orcid.org/0000-0002-2396-3534
References
- WidyaheningIS. The role of primary health care in the prevention of noncommunicable diseases. Rev Prim Care Prac and Educ. 2019;2(1):5–7.
- Royal Pharmaceutical Society. Medicines Optimisation:Helping patients to make the most of medicines Available from https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Policy/helping-patients-make-the-most-of-their-medicines.pdf. Accessed 06 June 2021.
- GarfieldS, BarberN, WalleyP, et al. Quality of medication use in primary care—mapping the problem, working to a solution: a systematic review of the literature. BMC Med. 2009;7:50. https://doi.org/10.1186/1741-7015-7-50.
- National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guidelines [NG5], 2015.
- NHS England. Medicines optimisation. Available from https://www.england.nhs.uk/medicines-2/medicines-optimisation/. Accessed 06 June 2021.
- SyedMA, AlnuaimiAS, ZainelAJ, et al. Prevalence of non-communicable diseases by age, gender and nationality in publicly funded primary care settings in Qatar. BMJ Nutr Prev Health. 2019. https://doi.org/10.1136/bmjnph-2018-000014.
- SyedMA, AlnuaimiAS, ZainelAJ, et al. Prevalence of Metabolic Syndrome in Primary Health settings in Qatar: a cross sectional study. BMC Public Health. 2020;20:611. https://doi.org/10.1186/s12889-020-08609-5.
- DavisJC, VerhagenE, BryanS, et al. 2014 consensus statement from the first Economics of Physical Inactivity Consensus (EPIC) conference (Vancouver). Br J Sports Med. 2014;48(12):947–951. https://doi.org/10.1136/bjsports-2014-093575.
- EzzatiM, RiboliE. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science. 2012;337(6101):1482–1487. https://doi.org/10.1126/science.1227001.
- KontisV, MathersCD, RehmJ, et al. Contribution of six risk factors to achieving the 25x25 non-communicable disease mortality reduction target: a modelling study. Lancet. 2014;384(9941):427–437. https://doi.org/10.1016/s0140-6736(14)60616-4.
- WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD): World Health Organization 2003 [cited 2020 10/03/2020]. https://www.who.int/standards/classifications/other-classifications/the-anatomical-therapeutic-chemical-classification-system-with-defined-daily-doses. Accessed 06 June 2021.
- HagstromB, MattssonB, WimoA, et al. More illness and less disease? A 20-year perspective on chronic disease and medication. Scand J Public Health. 2006;34(6):584–588. https://doi.org/10.1080/14034940600703407.
- AlsuwaidanA, AlmedlejN, AlsabtiS, et al. A comprehensive overview of polypharmacy in elderly patients in Saudi Arabia. Geriatrics. 2019;4:2. https://doi.org/10.3390/geriatrics4020036.
- RahimHF, SibaiA, KhaderY, et al. Non-communicable diseases in the Arab world. Lancet. 2014;383(9914):356–367 https://doi.org/10.1016/s0140-6736(13)62383-1.
- Al RasadiK, AlmahmeedW, AlHabibKF, et al. Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis. 2016;252:182–187. https://doi.org/10.1016/j.atherosclerosis.2016.07.925.
- Al-MaatouqM, Al-AroujM, AssaadSH, et al. Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin. Int J Clin Pract. 2010;64(2):149–159. https://doi.org/10.1111/j.1742-1241.2009.02235.x.
- van den AkkerM, VaesB, GoderisG, et al. Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015. PLoS ONE. 2019;14(2):e0212046. https://doi.org/10.1371/journal.pone.0212046.